JPH0220605B2 - - Google Patents

Info

Publication number: JPH0220605B2
Authority: JP; Japan
Prior art keywords: collagen; gelatin; drug; aqueous; sustained
Prior art date: 1982-09-09
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Expired

Application number

JP15583182A

Other languages

English (en)

Japanese (ja)

Other versions

JPS5946215A (ja

Inventor

Tsuneyoshi Nagagawa

Oiki Nandaka

Ryoji Machida

Shigeru Takeda

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Teijin Ltd

Original Assignee

Teijin Ltd

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1982-09-09

Filing date

1982-09-09

Publication date

1990-05-10

1982-09-09 Application filed by Teijin Ltd filed Critical Teijin Ltd

1982-09-09 Priority to JP15583182A priority Critical patent/JPS5946215A/ja

1984-03-15 Publication of JPS5946215A publication Critical patent/JPS5946215A/ja

1990-05-10 Publication of JPH0220605B2 publication Critical patent/JPH0220605B2/ja

Status Granted legal-status Critical Current

Links

108010035532 Collagen Proteins 0.000 claims description 58
102000008186 Collagen Human genes 0.000 claims description 58
229920001436 collagen Polymers 0.000 claims description 58
108010010803 Gelatin Proteins 0.000 claims description 54
229920000159 gelatin Polymers 0.000 claims description 54
239000008273 gelatin Substances 0.000 claims description 54
235000019322 gelatine Nutrition 0.000 claims description 54
235000011852 gelatine desserts Nutrition 0.000 claims description 54
239000003814 drug Substances 0.000 claims description 46
229940079593 drug Drugs 0.000 claims description 42
239000003094 microcapsule Substances 0.000 claims description 35
239000011162 core material Substances 0.000 claims description 31
238000013268 sustained release Methods 0.000 claims description 21
239000012730 sustained-release form Substances 0.000 claims description 21
239000000203 mixture Substances 0.000 claims description 17
239000002245 particle Substances 0.000 claims description 13
239000000126 substance Substances 0.000 claims description 9
239000002246 antineoplastic agent Substances 0.000 claims description 8
238000004519 manufacturing process Methods 0.000 claims description 7
229940041181 antineoplastic drug Drugs 0.000 claims description 6
GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 claims description 4
229960002949 fluorouracil Drugs 0.000 claims description 4
108010006654 Bleomycin Proteins 0.000 claims description 2
MWWSFMDVAYGXBV-RUELKSSGSA-N Doxorubicin hydrochloride Chemical compound Cl.O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 MWWSFMDVAYGXBV-RUELKSSGSA-N 0.000 claims description 2
229960001561 bleomycin Drugs 0.000 claims description 2
OYVAGSVQBOHSSS-UAPAGMARSA-O bleomycin A2 Chemical group N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC=C(N=1)C=1SC=C(N=1)C(=O)NCCC[S+](C)C)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1N=CNC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C OYVAGSVQBOHSSS-UAPAGMARSA-O 0.000 claims description 2
229960002918 doxorubicin hydrochloride Drugs 0.000 claims description 2
239000000243 solution Substances 0.000 description 24
239000007864 aqueous solution Substances 0.000 description 14
239000003921 oil Substances 0.000 description 9
235000019198 oils Nutrition 0.000 description 9
239000003795 chemical substances by application Substances 0.000 description 7
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 7
RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 6
238000003756 stirring Methods 0.000 description 6
238000007912 intraperitoneal administration Methods 0.000 description 5
239000003549 soybean oil Substances 0.000 description 5
235000012424 soybean oil Nutrition 0.000 description 5
SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 4
241001465754 Metazoa Species 0.000 description 4
238000005070 sampling Methods 0.000 description 4
108010045569 atelocollagen Proteins 0.000 description 3
239000003405 delayed action preparation Substances 0.000 description 3
230000000694 effects Effects 0.000 description 3
239000012528 membrane Substances 0.000 description 3
239000008213 purified water Substances 0.000 description 3
IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
239000001856 Ethyl cellulose Substances 0.000 description 2
ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 2
DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 2
NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 description 2
ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 2
238000007605 air drying Methods 0.000 description 2
150000001413 amino acids Chemical class 0.000 description 2
201000011510 cancer Diseases 0.000 description 2
239000011248 coating agent Substances 0.000 description 2
238000000576 coating method Methods 0.000 description 2
239000003937 drug carrier Substances 0.000 description 2
238000001035 drying Methods 0.000 description 2
238000004945 emulsification Methods 0.000 description 2
235000019325 ethyl cellulose Nutrition 0.000 description 2
229920001249 ethyl cellulose Polymers 0.000 description 2
230000014759 maintenance of location Effects 0.000 description 2
239000000463 material Substances 0.000 description 2
238000000034 method Methods 0.000 description 2
102000004169 proteins and genes Human genes 0.000 description 2
108090000623 proteins and genes Proteins 0.000 description 2
239000007974 sodium acetate buffer Substances 0.000 description 2
BHZOKUMUHVTPBX-UHFFFAOYSA-M sodium acetic acid acetate Chemical compound [Na+].CC(O)=O.CC([O-])=O BHZOKUMUHVTPBX-UHFFFAOYSA-M 0.000 description 2
239000012085 test solution Substances 0.000 description 2
229940124597 therapeutic agent Drugs 0.000 description 2
NAALWFYYHHJEFQ-ZASNTINBSA-N (2s,5r,6r)-6-[[(2r)-2-[[6-[4-[bis(2-hydroxyethyl)sulfamoyl]phenyl]-2-oxo-1h-pyridine-3-carbonyl]amino]-2-(4-hydroxyphenyl)acetyl]amino]-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid Chemical compound N([C@@H](C(=O)N[C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C=1C=CC(O)=CC=1)C(=O)C(C(N1)=O)=CC=C1C1=CC=C(S(=O)(=O)N(CCO)CCO)C=C1 NAALWFYYHHJEFQ-ZASNTINBSA-N 0.000 description 1
206010003445 Ascites Diseases 0.000 description 1
241000283690 Bos taurus Species 0.000 description 1
SGHZXLIDFTYFHQ-UHFFFAOYSA-L Brilliant Blue Chemical compound [Na+].[Na+].C=1C=C(C(=C2C=CC(C=C2)=[N+](CC)CC=2C=C(C=CC=2)S([O-])(=O)=O)C=2C(=CC=CC=2)S([O-])(=O)=O)C=CC=1N(CC)CC1=CC=CC(S([O-])(=O)=O)=C1 SGHZXLIDFTYFHQ-UHFFFAOYSA-L 0.000 description 1
239000004471 Glycine Substances 0.000 description 1
206010028980 Neoplasm Diseases 0.000 description 1
108091005804 Peptidases Proteins 0.000 description 1
239000004365 Protease Substances 0.000 description 1
102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 1
241000973887 Takayama Species 0.000 description 1
WFWLQNSHRPWKFK-UHFFFAOYSA-N Tegafur Chemical compound O=C1NC(=O)C(F)=CN1C1OCCC1 WFWLQNSHRPWKFK-UHFFFAOYSA-N 0.000 description 1
238000002835 absorbance Methods 0.000 description 1
238000010521 absorption reaction Methods 0.000 description 1
239000002253 acid Substances 0.000 description 1
230000002378 acidificating effect Effects 0.000 description 1
239000004480 active ingredient Substances 0.000 description 1
239000003513 alkali Substances 0.000 description 1
125000000539 amino acid group Chemical group 0.000 description 1
239000002585 base Substances 0.000 description 1
229920002988 biodegradable polymer Polymers 0.000 description 1
239000004621 biodegradable polymer Substances 0.000 description 1
210000000988 bone and bone Anatomy 0.000 description 1
235000012745 brilliant blue FCF Nutrition 0.000 description 1
239000004161 brilliant blue FCF Substances 0.000 description 1
229940055580 brilliant blue fcf Drugs 0.000 description 1
244000309464 bull Species 0.000 description 1
238000011088 calibration curve Methods 0.000 description 1
239000002775 capsule Substances 0.000 description 1
238000005119 centrifugation Methods 0.000 description 1
210000002808 connective tissue Anatomy 0.000 description 1
238000001816 cooling Methods 0.000 description 1
239000002285 corn oil Substances 0.000 description 1
235000005687 corn oil Nutrition 0.000 description 1
238000004132 cross linking Methods 0.000 description 1
230000001186 cumulative effect Effects 0.000 description 1
229960003109 daunorubicin hydrochloride Drugs 0.000 description 1
238000004925 denaturation Methods 0.000 description 1
230000036425 denaturation Effects 0.000 description 1
201000010099 disease Diseases 0.000 description 1
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
238000004090 dissolution Methods 0.000 description 1
230000000857 drug effect Effects 0.000 description 1
230000002500 effect on skin Effects 0.000 description 1
238000001914 filtration Methods 0.000 description 1
238000010438 heat treatment Methods 0.000 description 1
125000001841 imino group Chemical group [H]N=* 0.000 description 1
210000003041 ligament Anatomy 0.000 description 1
244000005700 microbiome Species 0.000 description 1
229960004857 mitomycin Drugs 0.000 description 1
239000004570 mortar (masonry) Substances 0.000 description 1
229910052757 nitrogen Inorganic materials 0.000 description 1
239000003960 organic solvent Substances 0.000 description 1
206010034674 peritonitis Diseases 0.000 description 1
229920000642 polymer Polymers 0.000 description 1
238000011002 quantification Methods 0.000 description 1
238000005185 salting out Methods 0.000 description 1
238000007873 sieving Methods 0.000 description 1
210000003491 skin Anatomy 0.000 description 1
230000003381 solubilizing effect Effects 0.000 description 1
230000002459 sustained effect Effects 0.000 description 1
238000002636 symptomatic treatment Methods 0.000 description 1
210000002435 tendon Anatomy 0.000 description 1

Landscapes

Medicinal Preparation (AREA)

JP15583182A 1982-09-09 1982-09-09 徐放性マイクロカプセルおよびその製造法 Granted JPS5946215A (ja)

Priority Applications (1)

Application Number	Priority Date	Filing Date	Title
JP15583182A JPS5946215A (ja)	1982-09-09	1982-09-09	徐放性マイクロカプセルおよびその製造法

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
JP15583182A JPS5946215A (ja)	1982-09-09	1982-09-09	徐放性マイクロカプセルおよびその製造法

Publications (2)

Publication Number	Publication Date
JPS5946215A JPS5946215A (ja)	1984-03-15
JPH0220605B2 true JPH0220605B2 (fr)	1990-05-10

Family

ID=15614444

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
JP15583182A Granted JPS5946215A (ja)	1982-09-09	1982-09-09	徐放性マイクロカプセルおよびその製造法

Country Status (1)

Country	Link
JP (1)	JPS5946215A (fr)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
FR2524312B1 (fr) *	1982-04-01	1985-10-04	Tech Cuir Centre	Nouvelles formes de micro-encapsulation de substances medicamenteuses par des couches homogenes de collagene natif
JPH062665B2 (ja) *	1987-10-06	1994-01-12	新田ゼラチン株式会社	ゼラチン組成物
JPH01123626A (ja) *	1987-11-06	1989-05-16	Terumo Corp	被覆型マイクロカプセルおよびその製造法
JPH01157349A (ja) *	1987-12-15	1989-06-20	Nippon Oil & Fats Co Ltd	麺類の物性改良法
JPH01168337A (ja) *	1987-12-25	1989-07-03	Terumo Corp	被覆型マイクロカプセルおよびその製造法
CN109126488A (zh) *	2018-08-22	2019-01-04	中南林业科技大学	一种抑菌型超滤膜及其制备方法

1982
- 1982-09-09 JP JP15583182A patent/JPS5946215A/ja active Granted

Also Published As

Publication number	Publication date
JPS5946215A (ja)	1984-03-15

Publication	Publication Date	Title
DE69213739T2 (de)	1997-02-20	Osteogene proteine enthaltende arzneimittel
JP3403203B2 (ja)	2003-05-06	ダリフェナシン含有製剤
DE69430491T2 (de)	2002-08-08	Verfahren zur verkapselung von nsaids
US5904937A (en)	1999-05-18	Taste masked pharmaceutical compositions
EP1248596B1 (fr)	2007-03-07	Kit a implantation comprenant une phase de support et un solvent
US20020009415A1 (en)	2002-01-24	Microspheres for use in the treatment of cancer
US20030166508A1 (en)	2003-09-04	Biologically active oral preparation that can be site-specific released in colon
EP0068191A2 (fr)	1983-01-05	Formes orales du dipyridamole
EA003161B1 (ru)	2003-02-27	Способ получения покрытых гранул со скрытым вкусом и немедленным высвобождением активного ингредиента
SK287484B6 (sk)	2010-11-08	Farmaceutický prostriedok s obsahom fenofibrátu a spôsob jeho prípravy
JPH05500961A (ja)	1993-02-25	タンパク質マイクロスフェア組成物
EP1722821B1 (fr)	2016-01-13	Composition destinee a l'administration orale d'hydrochlorure de tamsulosine et formulation en granules a liberation controlee comprenant cette composition
KR100258642B1 (ko)	2000-08-01	신속하게 용해되는 경구 제형
JPH0220605B2 (fr)	1990-05-10
JPH08268905A (ja)	1996-10-15	コロイド状絹フィブロイン及びそれを含有する組成物
RU2375047C2 (ru)	2009-12-10	Фармацевтическая лекарственная форма, устойчивая к действию желудочного сока, включающая n-(2-(2-фталимидоэтокси)ацетил)-l-аланил-d-глутаминовую кислоту (lk 423)
JP2003520770A (ja)	2003-07-08	硫酸モルヒネ微小顆粒、その調製方法およびそれを含有する組成物
CN116407509B (zh)	2024-11-15	一种利格列汀长效缓释微球及其制备方法
AU2002242084B2 (en)	2006-11-16	Methods and compositions for reducing the taste of pharmaceutically active agents
CN1476825A (zh)	2004-02-25	谷物类醇溶蛋白微球和制备方法
JP3372558B2 (ja)	2003-02-04	マイクロカプセル型徐放性製剤及びその製造法
JP2005518406A (ja)	2005-06-23	鎮静非ベンゾヂアゼピン製剤
EP1423099A1 (fr)	2004-06-02	Nouvelle forme posologique orale a liberation prolongee
US20060269606A1 (en)	2006-11-30	Cores and microcapsules suitable for parenteral administration as well as process for their manufacture
DE69802943T2 (de)	2002-08-01	Arzneizubereitung zur verabreichung von thiocolchicosid durch die mundschleimhaut